Sugammadex and Decreased Time to Extubation

Trial Purpose and Description

To demonstrate faster time to extubation after arrival in the cardiothoracic ICU in patients undergoing isolated CABG who receive study drug (Sugammadex 2mg/kg) as compared to placebo.

Ages: 21 years and younger

Gender: Both


Eligibility Criteria

Inclusion Criteria:

  • All elective isolated CABG cases in adult patients with preoperative left ventricular ejection fraction (LVEF) ≥45%.

Exclusion Criteria:

  • Emergency/unplanned cases.
  • EF<45% or moderate /severe RV dysfunction.
  • Estimated GFR < 30 mL/min.
  • Patients on supplemental oxygen at baseline (home oxygen).
  • BMI>40 (calculated as the patient's weight in kilograms divided by the square of the patient's height in meters).
  • Patients with chronic opioid use preoperatively.
  • Patients with known neuromuscular disorders preoperatively.
  • Patients with a known sensitivity to Rocuronium or to Sugammadex.
  • Patients with known cognitive deficits preoperatively.

Exclusions after recruitment but prior to randomization:

  • Postoperative Bleeding (chest tube output >100cc/hr ).
  • Treatment of anaphylactoid reaction intraoperatively.
  • Patient's temperature<36.2 or >38.3 degree Celsius at the time of ICU arrival.
  • Determination that the patient will require prolonged mechanical ventilation possibly requiring muscle relaxation based on the intraoperative course and clinical judgment of the study PI or collaborating intensivists.
  • Intraoperative hypoxia or on arrival to the ICU. (Please see Study Flowchart).
  • Cardiac arrest.
  • Sudden arrhythmia (Ventricular tachycardia runs/sudden bradycardia with improper pacemaker detection/function) precluding fast-track extubation protocol.
  • Need for inotrope initiation precluding fast-track protocol.
  • Postoperative ST changes.

Merck Sharp & Dohme

Start Date: 09/18/2017

End Date: 12/31/2017

Last Updated: 02/22/2018

Study HIC#: 2000021124

Get Involved

For more information about this study, contact:
Karen B Stavris
+1 203-737-5037
karen.stavris@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image